Brief: X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor
13/11/2024 12:38
Nov 13 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM
COMPLETED
SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA
(CN)
* X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN
ABSOLUTE
NEUTROPHIL COUNTS
* X4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN
G-CSF
DOSING WHILE MAINTAINING ANC
* X4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH
NO
SERIOUS ADVERSE EVENTS
Source text: urn:newsml:reuters.com:*:nGNX9zwzFh
Further company coverage: XFOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule